[ad_1]
According to its own information, the pharmaceutical authority, Anmat, issued an emergency registration for the sale of the prescription drug, limited to one year. The benefit-risk ratio of the product is acceptable, he said. At first it was not clear when the preparation was expected and how many doses the South American country should receive.
Also on Wednesday, the British drug regulatory agency granted emergency approval to the vaccine from British-Swedish pharmaceutical company AstraZeneca and the University of Oxford. Studies showed that the drug was less effective than the BioNTech and Pfizer vaccine, which has already been approved in some countries, including Argentina. However, it can be stored with much less effort and is significantly cheaper. According to the British Ministry of Health, it also offers protection against Covid 19 disease after the first of two vaccinations.
Just on Tuesday, Argentina began to administer the “Sputnik V” vaccine developed by Russian researchers. The vaccine was launched in Russia in mid-August and has been used there since the beginning of this month. Last week, Russia and AstraZeneca signed a memorandum to collaborate on vaccine development.
According to official figures, Argentina, which has around 45 million inhabitants, ranks twelfth in the world with 1.6 million corona infections, just behind Germany, which has almost twice the population. So far, more than 43,000 deaths related to the Covid 19 disease have been registered in Argentina.
/ nk / DP / fba
BUENOS AIRES (dpa-AFX)
More news on Pfizer Inc.
Image Sources: Elzbieta Krzysztof / Shutterstock.com
